Your search for non small cell lung cancer returned 44 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

News remove

Your search for non small cell lung cancer returned 44 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

PARP Inhibitor Veliparib Gets Orphan Drug Status from FDA

AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an investigational combination with chemotherapies or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
Drug News

BRAF V600 Targetable in Some Nonmelanoma Cancers

For some, but not all, nonmelanoma cancers, BRAF V600 is a targetable oncogene, with activity seen in non-small-cell lung cancer and Erdheim-Chester disease and Langerhans'-cell histiocytosis.
Drugs in the Pipeline

sNDA Accepted, Priority Review Granted to Tarceva for Genetically Distinct NSCLC

Astellas announced that the FDA has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations; the application has been granted Priority Review status.
News

Companion Dx Test for Iressa Receives Marketing Approval

Qiagen announced that it has received marketing approval for its therascreen EFGR RGQ PCR Kit as a companion diagnostic to Iressa (geftinib; AstraZeneca) for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).